Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | GSK3A | P49840 | 8/20 | 0.50 |
| ▸ | GSK3B | P49841 | 8/20 | 0.50 |
| ▸ | MGLL | Q99685 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220386 | 1.00 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL28886326 | 1.00 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL16274020 | 1.00 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL14850663 | 1.00 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL20176213 | 1.00 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL186221 | 0.98 | MEN1 (0.62) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL2788487 | 0.93 | MEN1 (0.59) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL3138532 | 0.85 | GSK3A (0.56) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL3794356 | 0.83 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL20176216 | 0.82 | MAPT (0.54) | MEN1KMT2AGAAALDH1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110068529-B | Characterization method of outer vesicle | 中国科学院深圳先进技术研究院 | 2023-06-23 | — | — | CN | claimed |
| US-20230025694-A1 | Silicone Hydrogel Based Fluorescent Assay and Contact Lens | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | claimed |
| CN-109715066-B | Silicone hydrogel based fluorescence assays and contact lenses | 巴尔的摩马里兰大学 | 2022-04-05 | — | — | CN | claimed |
| US-20200229740-A1 | Silicone Hydrogel Based Fluorescent Assay and Contact Lens | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-23 | — | — | US | claimed |
| CN-110068529-A | A kind of characterizing method of outer vesica | 中国科学院深圳先进技术研究院 | 2019-07-30 | — | — | CN | claimed |
| EP-3487406-A1 | SILICONE HYDROGEL BASED FLUORESCENT ASSAY AND CONTACT LENS | University of Maryland, Baltimore (US) | 2019-05-29 | — | — | EP | claimed |
| CN-109715066-A | Fluoremetry and haptic lens based on siloxanes aquogel | 巴尔的摩马里兰大学 | 2019-05-03 | — | — | CN | claimed |
| EP-3307243-A1 | DIAGNOSTIC TEST FOR EARLY STAGE CANCER | The Board of Regents of The University of Texas System (US) | 2018-04-18 | — | — | EP | claimed |
| WO-2018017842-A1 | SILICONE HYDROGEL BASED FLUORESCENT ASSAY AND CONTACT LENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-01-25 | — | — | WO | claimed |
| WO-2016201064-A1 | DIAGNOSTIC TEST FOR EARLY STAGE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-15 | — | — | WO | claimed |
| WO-2005047481-A2 | NOVEL SEQUENCES ENCODING HAPATITIS C VIRUS GLYCOPROTEINS | PROGENICS PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| EP-0738330-A4 | METHODS FOR USING RESONANCE ENERGY TRANSFER-BASED ASSAY OF HIV-1 ENVELOPE CLYCOPROTEIN-MEDIATED MEMBRANE FUSION, AND KITS FOR PRACTICING SAME | PROGENICS PHARM INC (US) | 2002-10-30 | — | — | EP | claimed |
| US-6468763-B1 | Optical detection of transmembrane potential changes | CALIPER TECHNOLOGIES CORP. | 2002-10-22 | — | — | US | claimed |
| EP-1039834-A4 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2001-12-05 | — | — | EP | claimed |
| US-6261763-B1 | CONTACTING SAMPLE WITH A TEST AGENT, CLUSTER DETERMINANT CELLS AND ENVELOPE GLYCOPROTEIN CELLS TO DETERMINE THE AGENTS ABILITY TO INHIBIT CELL FUSION; CELLS WERE LABELED WITH DIFFERENT DYES ALLOWING RESONANCE ENERGY TRANSFER | PROGENICS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | claimed |
| EP-1039834-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 2000-10-04 | — | — | EP | claimed |
| US-6123923-A | ADMINISTERING A PATIENT A CONTRAST AGENT CONTAINING A STABILIZER, A PHOTOACTIVE AGENT, A GASEOUS PRECURSOR SUCH AS PERFLUORINATED COMPOUND OR GAS OR BOTH, AND SCANNING THE PATIENT USING ULTRASOUND IMAGING AND OPTICAL IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-26 | — | — | US | claimed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-0738330-A1 | METHODS FOR USING RESONANCE ENERGY TRANSFER-BASED ASSAY OF HIV-1 ENVELOPE CLYCOPROTEIN-MEDIATED MEMBRANE FUSION, AND KITS FOR PRACTICING SAME | PROGENICS PHARMACEUTICALS, INC. (US) | 1996-10-23 | — | — | EP | claimed |
| WO-1995016789-A1 | METHODS FOR USING RESONANCE ENERGY TRANSFER-BASED ASSAY OF HIV-1 ENVELOPE CLYCOPROTEIN-MEDIATED MEMBRANE FUSION, AND KITS FOR PRACTICING SAME | PROGENICS PHARMACEUTICALS, INC. (US) | 1995-06-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025694-A1 | Silicone Hydrogel Based Fluorescent Assay and Contact Lens | CD44, CRYAA, IGFBP1 | MEN1 901/4885KMT2A 4319/4885GAA 1822/4885 |
| US-20200229740-A1 | Silicone Hydrogel Based Fluorescent Assay and Contact Lens | CD44, CRYAA, IGFBP1 | MEN1 901/4885KMT2A 4319/4885GAA 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.